Clinical Trials | A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 =50%
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 =50%
The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have advanced non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 =50%. As part of this study, you will either be treated with an investigational combination, a LAG-3 inhibitor, in combination with a PD-1 inhibitor or a PD-1 inhibitor alone. Both medications are administered by IV. The aim of the study is to see how effective theinvestigational combination is in treating advanced NSCLC, in comparison with PD-1 inhibitor. If you choose to be in this study, your part in the study is expected to last up to 5 years. • Screening phase: about 28 days • Treatment phase: up to ~2 years • Post-treatment phase (until end of survival follow up): up to ~3 years Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05785767